136.02
1.51%
2.02
After Hours:
136.50
0.48
+0.35%
Illumina Inc stock is traded at $136.02, with a volume of 9.10M.
It is up +1.51% in the last 24 hours and up +3.30% over the past month.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
See More
Previous Close:
$134.00
Open:
$133.45
24h Volume:
9.10M
Relative Volume:
4.60
Market Cap:
$21.57B
Revenue:
$4.39B
Net Income/Loss:
$-1.58B
P/E Ratio:
-5.1116
EPS:
-26.61
Net Cash Flow:
$546.00M
1W Performance:
-5.46%
1M Performance:
+3.30%
6M Performance:
+25.65%
1Y Performance:
-0.64%
Illumina Inc Stock (ILMN) Company Profile
Name
Illumina Inc
Sector
Industry
Phone
(858) 202-4500
Address
5200 ILLUMINA WAY, SAN DIEGO, CA
Compare ILMN with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
ILMN
Illumina Inc
|
136.02 | 21.57B | 4.39B | -1.58B | 546.00M | -9.96 |
TMO
Thermo Fisher Scientific Inc
|
524.05 | 200.45B | 42.37B | 6.14B | 7.78B | 15.95 |
DHR
Danaher Corp
|
228.55 | 165.08B | 23.74B | 3.89B | 4.98B | 5.24 |
A
Agilent Technologies Inc
|
134.51 | 38.36B | 6.51B | 1.29B | 1.37B | 4.42 |
IQV
Iqvia Holdings Inc
|
197.27 | 35.80B | 15.32B | 1.41B | 1.96B | 7.62 |
IDXX
Idexx Laboratories Inc
|
412.26 | 33.76B | 3.84B | 866.24M | 792.60M | 10.37 |
Illumina Inc Stock (ILMN) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-11-24 | Downgrade | Citigroup | Buy → Neutral |
Nov-12-24 | Resumed | Morgan Stanley | Equal-Weight |
Oct-17-24 | Upgrade | HSBC Securities | Hold → Buy |
Aug-28-24 | Upgrade | Argus | Hold → Buy |
Aug-16-24 | Upgrade | Daiwa Securities | Neutral → Buy |
Aug-14-24 | Upgrade | Barclays | Underweight → Equal Weight |
Aug-14-24 | Upgrade | TD Cowen | Hold → Buy |
Jul-10-24 | Upgrade | Citigroup | Neutral → Buy |
Jun-03-24 | Resumed | Jefferies | Hold |
Jan-16-24 | Downgrade | HSBC Securities | Buy → Hold |
Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
Dec-18-23 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
Dec-15-23 | Upgrade | Bernstein | Underperform → Mkt Perform |
Dec-14-23 | Initiated | Guggenheim | Buy |
Dec-14-23 | Initiated | Stephens | Overweight |
Dec-13-23 | Initiated | Wolfe Research | Outperform |
Dec-12-23 | Downgrade | BofA Securities | Neutral → Underperform |
Dec-11-23 | Upgrade | Citigroup | Sell → Neutral |
Nov-10-23 | Downgrade | Canaccord Genuity | Buy → Hold |
Sep-28-23 | Initiated | Bernstein | Underperform |
Jul-05-23 | Resumed | JP Morgan | Neutral |
Jan-25-23 | Downgrade | Argus | Buy → Hold |
Jan-05-23 | Initiated | Scotiabank | Sector Perform |
Dec-12-22 | Downgrade | Citigroup | Neutral → Sell |
Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
Oct-04-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
Sep-28-22 | Upgrade | Evercore ISI | In-line → Outperform |
Aug-25-22 | Initiated | Credit Suisse | Neutral |
Jul-13-22 | Downgrade | Barclays | Equal Weight → Underweight |
Jan-18-22 | Upgrade | Stifel | Hold → Buy |
Jan-11-22 | Upgrade | Barclays | Underweight → Equal Weight |
Jan-07-22 | Upgrade | BofA Securities | Underperform → Neutral |
Jan-06-22 | Resumed | Morgan Stanley | Equal-Weight |
Jan-06-22 | Resumed | Piper Sandler | Overweight |
Oct-15-21 | Resumed | Cowen | Outperform |
Aug-19-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
Jun-01-21 | Upgrade | Evercore ISI | Underperform → In-line |
Mar-31-21 | Downgrade | Atlantic Equities | Overweight → Neutral |
Mar-31-21 | Upgrade | Canaccord Genuity | Hold → Buy |
Mar-03-21 | Initiated | Barclays | Underweight |
Dec-22-20 | Upgrade | Piper Sandler | Neutral → Overweight |
Dec-17-20 | Upgrade | BTIG Research | Neutral → Buy |
Oct-13-20 | Downgrade | Guggenheim | Buy → Neutral |
Sep-30-20 | Initiated | Atlantic Equities | Overweight |
Sep-29-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
Sep-22-20 | Downgrade | Stifel | Buy → Hold |
Sep-22-20 | Downgrade | UBS | Buy → Neutral |
Sep-21-20 | Upgrade | Guggenheim | Neutral → Buy |
Sep-21-20 | Downgrade | JP Morgan | Overweight → Neutral |
Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
Aug-07-20 | Downgrade | Evercore ISI | In-line → Underperform |
Aug-07-20 | Downgrade | Piper Sandler | Overweight → Neutral |
Jul-07-20 | Downgrade | Guggenheim | Buy → Neutral |
Apr-24-20 | Downgrade | Citigroup | Buy → Neutral |
Apr-21-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
Jan-08-20 | Initiated | Wells Fargo | Underweight |
Jan-07-20 | Initiated | Citigroup | Buy |
Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
Nov-15-19 | Initiated | Stifel | Buy |
Oct-25-19 | Initiated | Guggenheim | Buy |
View All
Illumina Inc Stock (ILMN) Latest News
Illumina Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Illumina And Grail In 2025? Grounds For Optimism, If Mistakes Aren't Repeated (ILMN) - Seeking Alpha
Illumina, Inc. (ILMN) Sees Modest Gains Amid Regulatory Approvals and Market Speculation - Insider Monkey
Studying epigenetics to avoid unwanted effects of blood transfusions - Illumina
Franklin Resources Inc. Sells 70,305 Shares of Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
Video: Illumina showcases innovations at the 7th China International Import Expo - Illumina
Illumina Revolutionizes Healthcare: Inside Look at Leaders Shaping the Future of Genomics Technology - StockTitan
Metagenomics Market to See Booming Growth 2024-2031 | Bio-Rad - openPR
Explore our partnerships - Illumina
Ovation.io and Illumina Collaborate to Advance Genomic Data Research - BioSpace
Ovation and Illumina partner to advance precision medicine - Investing.com
Is There Now An Opportunity In Illumina, Inc. (NASDAQ:ILMN)? - Yahoo Finance
Illumina, Inc. (NASDAQ:ILMN) Stock Holdings Boosted by B. Riley Wealth Advisors Inc. - MarketBeat
DNA Test Kits Market Growth in Future Scope 2024-2031 | Devyser, - openPR
Y Intercept Hong Kong Ltd Cuts Stock Holdings in Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
Clinical Oncology Next Generation Sequencing Market Top - openPR
Genomic Cancer Testing Market Top PlayersIllumina, Inc., - openPR
Nasdaq 100 Shakeup: 3 Stocks That Can Gain - Investing.com
What's Going On With Illumina Stock On Monday?Illumina (NASDAQ:ILMN) - Benzinga
Sustainable Sequencing in the New MiSeq i100 Series - Yahoo Finance
Wilmington Savings Fund Society FSB Acquires New Position in Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
Toronto Dominion Bank Grows Position in Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
Illumina, Inc. (NASDAQ:ILMN) Sees Large Increase in Short Interest - MarketBeat
Illumina's SWOT analysis: stock faces pricing headwinds amid market leadership - Investing.com Australia
Geode Capital Management LLC Acquires 48,018 Shares of Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
MicroStrategy, Palantir, Axon Added To Nasdaq 100: Super Micro Computer, Moderna, Illumina Exit The Index - Benzinga
MicroStrategy, Palantir Added to Nasdaq 100, Moderna Removed - Bloomberg
Powering Singapore’s genomic research with AWS and Illumina - AWS Blog
Metagenomics Market Report by Product, Technology, - GlobeNewswire
Metagenomics Market Report by Product, Technology, Application, and Region (2024-2032) Featuring Profiles of Agilent Technologies, Enterome, Eurofins Scientific, Roche, Illumina, Novogene, PerkinElmer & More - Yahoo Finance
Illumina's WGS as A Game-Changer for Rapid Blood Cancer Diagnostics - Yahoo Finance
Bioinformatics Market Outlook: Trends, Regulatory Changes, - openPR
Teachers Retirement System of The State of Kentucky Has $6.62 Million Holdings in Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
Nomura Asset Management Co. Ltd. Raises Stake in Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
Public Employees Retirement System of Ohio Cuts Stock Holdings in Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
National Bank of Canada FI Sells 211,120 Shares of Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
DNA and Gene Chip Market to See Huge Growth by 2030 | Greiner Bio-One, Illumina Inc., LC Sciences - openPR
The Growing Case for Whole-Genome Sequencing in All Blood Cancers - Illumina
Gene Panel Market 2024 Size, Global Report till 2031 | Illumina, Inc, Thermo Fisher Scientific, Agilent Technologies. - openPR
What Does Illumina, Inc.'s (NASDAQ:ILMN) Share Price Indicate? - Simply Wall St
Vestcor Inc Acquires 9,600 Shares of Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
Citigroup Downgrades Illumina (ILMN) - MSN
Illumina stock outlook cautious with headwinds from China and macro conditions - Investing.com
Illumina (NASDAQ:ILMN) Cut to Neutral at Citigroup - MarketBeat
DNA Sequencing Market: An Analysis of Size, Shares, Business - openPR
Pillar Biosciences Announces Expansion of NGS Commercial Partnership with Illumina - The Eastern Progress Online
European Court of Justice rules in favor of Illumina in jurisdictional appeal - The Eastern Progress Online
Illumina Inc. stock outperforms competitors on strong trading day - MarketWatch
Independent Testing Proves Dragen Provides a Vastly More Comprehensive Genome - Yahoo Finance
A landmark Japanese study reaches 100,000 genomes - Illumina
Genomic Cancer Testing Market CAGR of 16.7% Share, Opportunities and Growth Forecast 2024-2031 | Illumina, - EIN News
Illumina Inc Stock (ILMN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):